Nairem (Tadalafil)

Tadalafil, the active ingredient in Nairem, is a Phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It treats erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia in adult patients.

GNH USA supplies Nairem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tadalafil acts on the phosphodiesterase‑5 pathway to improve vascular smooth‑muscle tone in several disease states.

- Erectile dysfunction: enhances the ability to achieve and maintain an erection when sexually stimulated. - Pulmonary arterial hypertension: lowers pulmonary arterial pressure and improves exercise capacity. - Benign prostatic hyperplasia: reduces urinary frequency and improves flow by relaxing smooth muscle in the prostate and bladder neck.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache - Flushing - Dyspepsia - Nasal congestion

Serious or Rare Side Effects: - Sudden vision loss (non‑arteritic anterior ischemic optic neuropathy) - Priapism lasting longer than 4 hours - Severe hypotension or syncope

Before prescribing, clinicians should consider several safety factors.

- Cardiovascular assessment: evaluate underlying heart disease before use. - Concomitant nitrate therapy: contraindicated due to risk of profound hypotension. - Severe renal or hepatic impairment: dose adjustment may be required. - Uncontrolled hypertension or hypotension: monitor blood pressure closely. - Retinitis pigmentosa or other retinal disorders: avoid use. - Store at ambient temperature: keep in the original pack, protect from moisture.

Tadalafil can interact with several medication classes.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin, isosorbide dinitrate) - Guanylate cyclase stimulators (e.g., riociguat) - Certain alpha‑blockers (e.g., doxazosin) in high doses

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) - CYP3A4 inducers (e.g., rifampin, carbamazepine) - Antihypertensive agents (e.g., beta‑blockers, calcium channel blockers) - Alcohol: may enhance hypotensive effect